Trials / Completed
CompletedNCT03423823
Ziv-aflibercept Efficacy in Better Regulating AMD
An Active-treatment Study of the Efficacy of Ziv-aflibercept in Patients With Neovascular Age-Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Kapil Kapoor · Academic / Other
- Sex
- All
- Age
- 50 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, open-label, interventional, controlled study to determine the effects of Zaltrap on Neovascularized Wet Macular Degeneration as compared to the control anti-vascular endothelial growth factor ("anti-VEGF") injections (bevacizumab, ranibizumab, or aflibercept).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ziv-Aflibercept 25 MG/ML [Zaltrap] | Anti-VEGF injection |
| DRUG | Ranibizumab | Anti-VEGF standard of care injection |
Timeline
- Start date
- 2017-07-07
- Primary completion
- 2020-06-26
- Completion
- 2020-06-26
- First posted
- 2018-02-06
- Last updated
- 2020-10-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03423823. Inclusion in this directory is not an endorsement.